Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GFER | P55789 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924450 | 0.85 | MEN1 (0.73) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14923988 | 0.84 | KMT2A (0.72) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19615305 | 0.83 | MEN1 (0.71) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL24745664 | 0.83 | MEN1 (0.71) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL18164586 | 0.83 | MEN1 (0.71) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4991662 | 0.83 | MEN1 (0.66) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6152910 | 0.81 | MAPT (0.58) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1926789 | 0.81 | MAPT (0.58) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19615186 | 0.80 | MEN1 (0.66) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL900049 | 0.79 | MAPT (0.61) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-7026314-B2 | Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist | ASTRAZENECA AB (SE) | 2006-04-11 | — | — | US | disclosed |
| US-20060019947-A1 | Therapeutic chromone compounds | CHAPDELAINE MARC | 2006-01-26 | — | — | US | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003037871-A1 | THERAPEUTIC QUINOLONE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | KMT2A 2073/4885MEN1 382/4885MAPT 698/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | KMT2A 910/4885MEN1 192/4885MAPT 628/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | KMT2A 1315/4885MEN1 285/4885MAPT 653/4885 |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | KMT2A 669/4885MEN1 1940/4885MAPT 1943/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | KMT2A 1265/4885MEN1 215/4885MAPT 661/4885 |
| US-20060019947-A1 | Therapeutic chromone compounds | HTR1B, HTR3B, HTR1A | KMT2A 2249/4885MEN1 419/4885MAPT 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.